Koylu B, Esen B, Bektas S, Ozbek L, Turan V, Urman B
Sci Rep. 2025; 15(1):7770.
PMID: 40044844
PMC: 11883018.
DOI: 10.1038/s41598-025-91476-0.
Silvestris E, DOronzo S, Petracca E, DAddario C, Cormio G, Loizzi V
J Pers Med. 2024; 14(4).
PMID: 38673058
PMC: 11050999.
DOI: 10.3390/jpm14040431.
Ntemou E, Delgouffe E, Goossens E
Cancers (Basel). 2024; 16(6).
PMID: 38539511
PMC: 10968841.
DOI: 10.3390/cancers16061176.
Suijkerbuijk K, van Eijs M, van Wijk F, Eggermont A
Nat Cancer. 2024; 5(4):557-571.
PMID: 38360861
DOI: 10.1038/s43018-024-00730-3.
Hoffmann I, Greither T, Behre H
Dermatologie (Heidelb). 2023; 74(7):490-495.
PMID: 37286872
DOI: 10.1007/s00105-023-05167-w.
The Impact of Systemic Oncological Treatments on the Fertility of Adolescents and Young Adults-A Systematic Review.
Himpe J, Lammerant S, Van den Bergh L, Lapeire L, De Roo C
Life (Basel). 2023; 13(5).
PMID: 37240854
PMC: 10223569.
DOI: 10.3390/life13051209.
The Uncharted Landscape of Rare Endocrine Immune-Related Adverse Events.
Mytareli C, Ziogas D, Karampela A, Papalexis P, Siampanopoulou V, Lafioniatis A
Cancers (Basel). 2023; 15(7).
PMID: 37046677
PMC: 10093286.
DOI: 10.3390/cancers15072016.
Cutaneous Melanoma and Hormones: Focus on Sex Differences and the Testis.
Cosci I, Grande G, Di Nisio A, Rocca M, Del Fiore P, Benna C
Int J Mol Sci. 2023; 24(1).
PMID: 36614041
PMC: 9820190.
DOI: 10.3390/ijms24010599.
Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy.
Albarran-Artahona V, Laguna J, Gorria T, Torres-Jimenez J, Pascal M, Mezquita L
Diagnostics (Basel). 2022; 12(9).
PMID: 36140493
PMC: 9498261.
DOI: 10.3390/diagnostics12092091.
Fertility and CAR T-cells: Current practice and future directions.
Ligon J, Fry A, Maher J, Foley T, Silbert S, Yates B
Transplant Cell Ther. 2022; 28(9):605.e1-605.e8.
PMID: 35705177
PMC: 10332466.
DOI: 10.1016/j.jtct.2022.06.002.
Prescription Patterns, Recurrence, and Toxicity Rates of Adjuvant Treatment for Stage III/IV Melanoma-A Real World Single-Center Analysis.
Hoffmann M, Hayoz S, Ozdemir B
Biology (Basel). 2022; 11(3).
PMID: 35336796
PMC: 8945449.
DOI: 10.3390/biology11030422.
Immune-checkpoint inhibitors: long-term implications of toxicity.
Johnson D, Nebhan C, Moslehi J, Balko J
Nat Rev Clin Oncol. 2022; 19(4):254-267.
PMID: 35082367
PMC: 8790946.
DOI: 10.1038/s41571-022-00600-w.
Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy.
Wong S, Nebhan C, Johnson D
Front Immunol. 2021; 12:786046.
PMID: 34868071
PMC: 8635107.
DOI: 10.3389/fimmu.2021.786046.
Effects of PD-1 blockade on ovarian follicles in a prepubertal female mouse.
Xu P, Luan Y, Yu S, Xu J, Coulter D, Kim S
J Endocrinol. 2021; 252(1):15-30.
PMID: 34647523
PMC: 8630981.
DOI: 10.1530/JOE-21-0209.
Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review.
Garutti M, Lambertini M, Puglisi F
ESMO Open. 2021; 6(5):100276.
PMID: 34597942
PMC: 8487000.
DOI: 10.1016/j.esmoop.2021.100276.
Trainee-Led Quality Improvement Project to Improve Fertility Preservation Counseling for Patients With Cancer.
Sena L, Sedhom R, Scott S, Kagan A, Marple A, Canzoniero J
JCO Oncol Pract. 2021; 18(3):e403-e411.
PMID: 34565170
PMC: 8932487.
DOI: 10.1200/OP.21.00479.
Immune checkpoint inhibitor-related hypogonadism and infertility: a neglected issue in immuno-oncology.
Ozdemir B
J Immunother Cancer. 2021; 9(2).
PMID: 33589529
PMC: 7887354.
DOI: 10.1136/jitc-2020-002220.
